SLC5A2 and diabetes mellitus: HF incidences reduce among those using empagliflozin for a short period of time who have diabetes and cardiovascular disease, yet the precise mechanism through which SGLT-2 inhibitors have a discernible beneficial effect on cardiovascular events is uncertain [4,5,13,14].